company background image
MD

MEDNAX NYSE:MD Stock Report

Last Price

US$18.43

Market Cap

US$1.6b

7D

4.2%

1Y

-41.9%

Updated

19 May, 2022

Data

Company Financials +
MD fundamental analysis
Snowflake Score
Valuation3/6
Future Growth1/6
Past Performance3/6
Financial Health2/6
Dividends0/6

MD Stock Overview

MEDNAX, Inc., together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States and Puerto Rico.

MEDNAX Competitors

Price History & Performance

Summary of all time highs, changes and price drops for MEDNAX
Historical stock prices
Current Share PriceUS$18.43
52 Week HighUS$35.68
52 Week LowUS$17.17
Beta2.05
1 Month Change-22.37%
3 Month Change-21.17%
1 Year Change-41.92%
3 Year Change-28.62%
5 Year Change-66.72%
Change since IPO244.89%

Recent News & Updates

Shareholder Returns

MDUS HealthcareUS Market
7D4.2%-0.2%0.1%
1Y-41.9%1.8%-12.7%

Return vs Industry: MD underperformed the US Healthcare industry which returned 1.3% over the past year.

Return vs Market: MD underperformed the US Market which returned -11.5% over the past year.

Price Volatility

Is MD's price volatile compared to industry and market?
MD volatility
MD Average Weekly Movement6.3%
Healthcare Industry Average Movement10.4%
Market Average Movement8.0%
10% most volatile stocks in US Market17.0%
10% least volatile stocks in US Market3.0%

Stable Share Price: MD is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: MD's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19795,000Mark Ordanhttps://www.mednax.com

MEDNAX, Inc., together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States and Puerto Rico. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians. The company also provides maternal-fetal care services, including inpatient and office-based clinical care to expectant mothers and unborn babies through affiliated maternal-fetal medicine subspecialists, as well as obstetricians and other clinicians, including maternal-fetal nurse practitioners, certified nurse mid-wives, ultrasonographers, and genetic counselors.

MEDNAX Fundamentals Summary

How do MEDNAX's earnings and revenue compare to its market cap?
MD fundamental statistics
Market CapUS$1.60b
Earnings (TTM)US$81.72m
Revenue (TTM)US$1.95b

19.4x

P/E Ratio

0.8x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
MD income statement (TTM)
RevenueUS$1.95b
Cost of RevenueUS$1.43b
Gross ProfitUS$518.30m
Other ExpensesUS$436.58m
EarningsUS$81.72m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)0.95
Gross Margin26.62%
Net Profit Margin4.20%
Debt/Equity Ratio91.8%

How did MD perform over the long term?

See historical performance and comparison

Valuation

Is MEDNAX undervalued compared to its fair value and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry


>50%

Undervalued compared to fair value

Share Price vs. Fair Value

Below Fair Value: MD ($18.43) is trading below our estimate of fair value ($37.18)

Significantly Below Fair Value: MD is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: MD is poor value based on its PE Ratio (19.4x) compared to the US Healthcare industry average (18.4x).

PE vs Market: MD is poor value based on its PE Ratio (19.4x) compared to the US market (15.5x).


Price to Earnings Growth Ratio

PEG Ratio: MD is poor value based on its PEG Ratio (1.8x)


Price to Book Ratio

PB vs Industry: MD is good value based on its PB Ratio (1.8x) compared to the US Healthcare industry average (2.4x).


Future Growth

How is MEDNAX forecast to perform in the next 1 to 3 years based on estimates from 10 analysts?

Future Growth Score

1/6

Future Growth Score 1/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


10.6%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: MD's forecast earnings growth (10.6% per year) is above the savings rate (1.9%).

Earnings vs Market: MD's earnings (10.6% per year) are forecast to grow slower than the US market (12.4% per year).

High Growth Earnings: MD's earnings are forecast to grow, but not significantly.

Revenue vs Market: MD's revenue (6.9% per year) is forecast to grow slower than the US market (7.8% per year).

High Growth Revenue: MD's revenue (6.9% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if MD's Return on Equity is forecast to be high in 3 years time


Past Performance

How has MEDNAX performed over the past 5 years?

Past Performance Score

3/6

Past Performance Score 3/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-45.9%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: MD has a large one-off loss of $68.4M impacting its March 31 2022 financial results.

Growing Profit Margin: MD's current net profit margins (4.2%) are higher than last year (0.8%).


Past Earnings Growth Analysis

Earnings Trend: MD's earnings have declined by 45.9% per year over the past 5 years.

Accelerating Growth: MD's earnings growth over the past year (472.6%) exceeds its 5-year average (-45.9% per year).

Earnings vs Industry: MD earnings growth over the past year (472.6%) exceeded the Healthcare industry 8.8%.


Return on Equity

High ROE: MD's Return on Equity (9.3%) is considered low.


Financial Health

How is MEDNAX's financial position?

Financial Health Score

2/6

Financial Health Score 2/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: MD's short term assets ($439.8M) exceed its short term liabilities ($269.7M).

Long Term Liabilities: MD's short term assets ($439.8M) do not cover its long term liabilities ($1.2B).


Debt to Equity History and Analysis

Debt Level: MD's net debt to equity ratio (80.7%) is considered high.

Reducing Debt: MD's debt to equity ratio has increased from 68.7% to 91.8% over the past 5 years.

Debt Coverage: MD's debt is not well covered by operating cash flow (7.6%).

Interest Coverage: MD's interest payments on its debt are well covered by EBIT (4.2x coverage).


Balance Sheet


Dividend

What is MEDNAX current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate MD's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate MD's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if MD's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MD's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as MD has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

1.8yrs

Average management tenure


CEO

Mark Ordan (62 yo)

1.83yrs

Tenure

US$6,848,969

Compensation

Mr. Mark S. Ordan serves as Chief Executive Officer and Director at MEDNAX, Inc. since July 12, 2020. Mr. Ordan serves as a Director of The Carlyle Group Inc. since April 1, 2022. He joined MEDNAX, Inc. in...


CEO Compensation Analysis

Compensation vs Market: Mark's total compensation ($USD6.85M) is about average for companies of similar size in the US market ($USD5.41M).

Compensation vs Earnings: Mark's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: MD's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.


Board Members

Experienced Board: MD's board of directors are not considered experienced ( 2.4 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

MEDNAX, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: MEDNAX, Inc.
  • Ticker: MD
  • Exchange: NYSE
  • Founded: 1979
  • Industry: Health Care Services
  • Sector: Healthcare
  • Implied Market Cap: US$1.597b
  • Shares outstanding: 86.12m
  • Website: https://www.mednax.com

Number of Employees


Location

  • MEDNAX, Inc.
  • 1301 Concord Terrace
  • Sunrise
  • Florida
  • 33323
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/19 00:00
End of Day Share Price2022/05/19 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.